A Phase 2a, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D Virus Infection, Including a Randomised, Single Blinded, Placebo-controlled Exploratory Part
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs RBD 1016 (Primary)
- Indications Hepatitis D
- Focus Pharmacokinetics
- Sponsors Ribocure Pharmaceuticals
- 24 Oct 2024 New trial record